AgentMezigdomide (CELMoD)
Backbone+ carfilzomib-dexamethasone
EfficacyPFS 18 vs 8.3 mo (HR 0.48)
StatusNot yet approved
PositiveNot yet (approval)
SUCCESSOR-2
NCT05552976 · LBA5004 · Dimopoulos · 479 patients
- Mezigdomide + carfilzomib + dexamethasone vs carfilzomib-dexamethasone
- Median PFS 18.0 vs 8.3 months, HR 0.48, P<0.0001
- Neutropenia in line with expectations; discontinuation for it was rare
- Published in the Lancet on 14 June 2026
Why it matters: A next-generation CELMoD roughly doubled PFS and could become an accessible combination across care settings once approved.
PositiveInvestigational
ImmunoPRISM
Immuno-PRISM · NCT05469893 · Nadeem · phase 2
- Teclistamab vs lenalidomide-dexamethasone in high-risk smouldering myeloma
- Estimated 2-year PFS 92% vs 51%
- MRD-negativity at 10⁻⁵ of 81.2% vs 0%
- Complete response 75.6% vs none; no high-grade CRS or neurotoxicity
Why it matters: Striking depth of response, but this is phase 2 bispecific therapy in pre-malignant disease, so the risk-benefit balance needs longer follow-up.
WatchWatch
MonumenTAL-3
Talquetamab (GPRC5D) vs DPd
- Phase 3 talquetamab-based regimens vs daratumumab-pomalidomide-dexamethasone
- GPRC5D toxicity: dysgeusia, skin and nail changes, weight loss from taste disturbance
- Note: MajesTEC-9 is a separate teclistamab monotherapy trial presented at ASCO 2026, not EHA
Why it matters: Bispecifics continue to move into earlier myeloma lines; specific EHA 2026 efficacy figures for MonumenTAL-3 were not independently verified here.